Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2007

View Archived Issues

SuperGen presents overview of preclinical pipeline

Targeting topoisomerase II with R-16 induces apoptosis and cell cycle arrest in tumor cell lines

Recent patents disclose novel anticancer compounds

Resveratrol analogue M-8 active against melanoma cells

BAY-65-5811 and doxorubicin synergistic against melanoma cells

Hepatitis E virus vaccine effective in phase II study

Novel agents for inflammatory disorders disclosed in recent patents

Recent Merck Frosst patent describes new treatment option for atherosclerosis

HanAll licenses Nautilus compounds for South Korea

MK-2048 shows in vitro activity against resistant HIV-1 mutants

ProNAi and Novosom collaborate on DNAi-based cancer therapeutics

Novartis extends research collaboration with Idera

New formulation of oral methylnaltrexone begins clinical testing

Avalon and Merck & Co. collaborate in cancer

Phosphagenics extends transdermal technology platform

Affectis and Mitsubishi extend research collaboration

ZymoGenetics updates plans for rhThrombin

Crucell to receive funding in development of AdVac-based TB vaccine

Acrux and Organon sign new agreement in women's health

Novel polyamine biosynthesis inhibitor shows potential to prevent HIV/SIV-related encephalitis

ABT-894 begins phase II study for ADHD

Genta and IDIS sign compassionate use agreement for Ganite and Genasense

Stemline Therapeutics in-licenses worldwide rights to SL-401

RVX-208 completes toxicology studies on way to IND filing

NeuroVax studied in new phase II trial for relapsing-remitting MS

New phase I/II trial studies Ferritarg P for Hodgkin's disease

Financing at Potentia to support AMD program

AS-1404 with carboplatin and paclitaxel shows good response rate in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...